Analyst Ratings For Intra-Cellular Therapies
Analyst Ratings For Intra-Cellular Therapies
分析師對細胞內療法的評級
Throughout the last three months, 18 analysts have evaluated Intra-Cellular Therapies (NASDAQ:ITCI), offering a diverse set of opinions from bullish to bearish.
在過去的三個月中，有18位分析師對細胞內療法（納斯達克股票代碼：ITCI）進行了評估，提供了從看漲到看跌的不同觀點。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要概述了他們最近的評級，重點介紹了過去30天中情緒的變化，並將其與前幾個月進行了比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $91.94, a high estimate of $120.00, and a low estimate of $77.00. Marking an increase of 11.44%, the current average surpasses the previous average price target of $82.50.
分析師通過對12個月目標股價的評估提供了更深入的見解，顯示平均目標價爲91.94美元，最高估計爲120.00美元，低估值爲77.00美元。當前的平均價格上漲了11.44％，超過了之前的平均目標股價82.50美元。
Diving into Analyst Ratings: An In-Depth Exploration
深入分析師評級：深度探索
An in-depth analysis...
對分析師...
登入免費觀看全文
登入/註冊